{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:59Z","timestamp":1787019599894,"version":"build-2736575974"},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myelodysplastic syndrome (MDS)\/myeloproliferative neoplasm (MPN) overlap syndromes are uniquely classified neoplasms occurring in both children and adults. This category consists of 5 neoplastic subtypes: chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), BCR-ABL1\u2013negative atypical chronic myeloid leukemia (aCML), MDS\/MPN-ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T), and MDS\/MPN-unclassifiable (U). Cytogenetic abnormalities and somatic copy number variations are uncommon; however, &amp;gt;90% patients harbor gene mutations. Although no single gene mutation is specific to a disease subtype, certain mutational signatures in the context of appropriate clinical and morphological features can be used to establish a diagnosis. In CMML, mutated coexpression of TET2 and SRSF2 results in clonal hematopoiesis skewed toward monocytosis, and the ensuing acquisition of driver mutations including ASXL1, NRAS, and CBL results in overt disease. MDS\/MPN-RS-T demonstrates features of SF3B1-mutant MDS with ring sideroblasts (MDS-RS), with the development of thrombocytosis secondary to the acquisition of signaling mutations, most commonly JAK2V617F. JMML, the only pediatric entity, is a bona fide RASopathy, with germline and somatic mutations occurring in the oncogenic RAS pathway giving rise to disease. BCR-ABL1\u2013negative aCML is characterized by dysplastic neutrophilia and is enriched in SETBP1 and ETNK1 mutations, whereas MDS\/MPN-U is the least defined and lacks a characteristic mutational signature. Molecular profiling also provides prognostic information, with truncating ASXL1 mutations being universally detrimental and germline CBL mutations in JMML showing spontaneous regression. Sequencing information in certain cases can help identify potential targeted therapies (IDH1, IDH2, and splicing mutations) and should be a mainstay in the diagnosis and management of these neoplasms.<\/jats:p>","DOI":"10.1182\/hematology.2020000130","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T22:22:10Z","timestamp":1607120530000},"page":"450-459","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Genomics of myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes"],"prefix":"10.1182","volume":"2020","author":[{"given":"Mrinal M.","family":"Patnaik","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2020121621261059200_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood 2016;128(3):462-463]","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2020121621261059200_B2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"2020121621261059200_B3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1080\/10428194.2018.1429607","article-title":"FGFR1 rearranged hematological neoplasms: molecularly defined and clinically heterogeneous","volume":"59","author":"Patnaik","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2020121621261059200_B4","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/ajh.24267","article-title":"Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2020121621261059200_B5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am J Hematol"},{"issue":"12","key":"2020121621261059200_B6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2018-08-867333","article-title":"The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis","volume":"133","author":"Cargo","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020121621261059200_B7","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"HemaSphere"},{"issue":"1","key":"2020121621261059200_B8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.24581","article-title":"DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2020121621261059200_B9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-017-0045-4","article-title":"EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental","volume":"8","author":"Patnaik","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"2020121621261059200_B10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML): a study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"2020121621261059200_B11","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1002\/ajh.24861","article-title":"Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"92","author":"Vallapureddy","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2020121621261059200_B12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","article-title":"Age-related mutations and chronic myelomonocytic leukemia","volume":"30","author":"Mason","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2020121621261059200_B13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2020121621261059200_B14","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020121621261059200_B15","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1038\/bcj.2015.113","article-title":"Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"2020121621261059200_B16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"issue":"9","key":"2020121621261059200_B17","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1038\/s41375-020-0752-x","article-title":"Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS\/MPN overlap neoplasms","volume":"34","author":"DiFilippo","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2020121621261059200_B18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ajh.24939","article-title":"Therapy related chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"issue":"11","key":"2020121621261059200_B19","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia [published correction appears in Nat Genet 2016;48:101]","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"11","key":"2020121621261059200_B20","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3324\/haematol.2014.114595","article-title":"RAS diseases in children","volume":"99","author":"Niemeyer","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"2020121621261059200_B21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who\u2019s the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2020121621261059200_B22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2014-09-601690","article-title":"Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia","volume":"125","author":"Stieglitz","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020121621261059200_B23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ajh.25397","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: \u201c2019 Update on Diagnosis, Risk-stratification, and Management\u201d","volume":"94","author":"Patnaik","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"2020121621261059200_B24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"25","key":"2020121621261059200_B25","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2020121621261059200_B26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"2020121621261059200_B27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2020121621261059200_B28","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2020121621261059200_B29","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2020121621261059200_B30","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic\u2013Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"issue":"19","key":"2020121621261059200_B31","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2020121621261059200_B32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2020121621261059200_B33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"2020121621261059200_B34","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1038\/ncomms8307","article-title":"Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex","volume":"6","author":"Balasubramani","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"2020121621261059200_B35","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/leu.2017.190","article-title":"Molecular characterization of EZH2 mutant patients with myelodysplastic\/myeloproliferative neoplasms","volume":"31","author":"Rinke","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2020121621261059200_B36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"key":"2020121621261059200_B37","article-title":"Landscape of RAS pathway mutations in patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients [published online ahead of print 8 June 2020]","author":"Buradkar","journal-title":"Leukemia"},{"issue":"6","key":"2020121621261059200_B38","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.3324\/haematol.2018.208082","article-title":"Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation","volume":"104","author":"Patnaik","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2020121621261059200_B39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41375-018-0203-0","article-title":"Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML","volume":"33","author":"Niyongere","year":"2019","journal-title":"Leukemia"},{"issue":"25","key":"2020121621261059200_B40","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2020121621261059200_B41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"2020121621261059200_B42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2020121621261059200_B43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"2020121621261059200_B44","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am J Hematol"},{"issue":"12","key":"2020121621261059200_B45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic\u2013French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"issue":"12","key":"2020121621261059200_B46","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"6465","key":"2020121621261059200_B47","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"17","key":"2020121621261059200_B48","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2020121621261059200_B49","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood-2007-09-111831","article-title":"Genotype\u2013phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations","volume":"111","author":"Flotho","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2020121621261059200_B50","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3324\/haematol.2019.218677","article-title":"Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia","volume":"105","author":"Woo","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2020121621261059200_B51","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"2020121621261059200_B52","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"2020121621261059200_B53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/450\/1794997\/hem2020000130c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/450\/1794997\/hem2020000130c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T13:15:44Z","timestamp":1608297344000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/450\/474367\/Genomics-of-myelodysplastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000130","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}